SARS-CoV-2

Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?

August, 2021

Highlights

  • Infection-enhancing antibodies have been detected in symptomatic Covid-19
  • Antibody dependent enhancement (ADE) is a potential concern for vaccines
  • Enhancing antibodies recognize both the Wuhan strain and Delta variants
  • ADE of Delta variants is a potential risk for current vaccines
  • Vaccine formulations lacking ADE epitope are suggested

Abstract

Performance of the SARS-CoV-2 RT-PCR test as a tool for detecting SARS-CoV-2 infection in the population

DSA ADS Course - 2021

Performance of the SARS-CoV-2 RT-PCR test as a tool for detecting SARS-CoV-2 infection in the population

COVID19, Public Policy, Health Policy, SARS-CoV-2, RT-PCR Test, Infectious Potential, Laboratory Quality Assurance, Dr. Kary Mullis, Cycle Threshold Values

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

July, 2021

Highlights

  • Most recovered COVID-19 patients mount broad, durable immunity after infection
  • Neutralizing antibodies show a bi-phasic decay with half-lives >200 days
  • Spike IgG+ memory B cells increase and persist post-infection
  • Durable polyfunctional CD4 and CD8 T cells recognize distinct viral epitope regions

Summary

Effects of a Major Deletion in the SARS-CoV-2 Genome on the Severity of Infection and the Inflammatory Response

August, 2020

Abstract

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with a 382-nucleotide deletion (∆382) in the open reading frame 8 (ORF8) region of the genome have been detected in Singapore and other countries. We investigated the effect of this deletion on the clinical features of infection.

Methods

Pages